Michael Andrew Chambers bought $5.0M of SRPT
director at Sarepta Therapeutics, Inc.. 37,038 shares at an average of $133.80, traded Aug 16, 2024, filed Aug 20, 2024.
Score components
- +15RoleDirector
- +25Trade size$5.0M at market
- +3Relative to holdingsHoldings up 15%
- +4Price context19% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.5%, 3m -24.1%, 6m -25.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-098859, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 16, 2024 | POpen-market purchase Common Stockindirect: By Revocable Trust | +13,106 | $133.07 | $1.7M | 260,102 | Aug 20, 2024 |
| Aug 16, 2024 | POpen-market purchase Common Stockindirect: By Revocable Trust | +18,284 | $134.06 | $2.5M | 278,386 | Aug 20, 2024 |
| Aug 16, 2024 | POpen-market purchase Common Stockindirect: By Revocable Trust | +5,648 | $134.66 | $761k | 284,034 | Aug 20, 2024 |
Related signals
Other insiders at Sarepta Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | SRPTsell Sarepta Therapeutics, Inc. | Stephen Mayo director | $123k 7,239 shares | -80% | |
| 34Weak | SRPTsell Sarepta Therapeutics, Inc. | Ian Michael Estepan Chief Operating Officer | $294k 13,187 shares | -6% | |
| 43Moderate | Sarepta Therapeutics, Inc. | Hans Lennart Rudolf Wigzell director | $1.3M 10,500 shares | -31% | |
| 40Moderate | Sarepta Therapeutics, Inc. | Kathryn Jean Boor director | $205k 1,636 shares | -22% | |
| 50Moderate | SRPTsell Sarepta Therapeutics, Inc. | Ian Michael Estepan Chief Financial Officer | $822k 5,985 shares | -15% | |
| 23Weak | Sarepta Therapeutics, Inc. | Bilal Arif Chief Tech Ops Officer | $1.9M 11,757 shares | -40% | |
| 33Weak | Sarepta Therapeutics, Inc. | Ryan Edward Brown EVP, General Counsel | $6.3M 38,957 shares | -69% | |
| 18Weak | Sarepta Therapeutics, Inc. | Dallan Murray Chief Customer Officer | $509k 3,635 shares | -17% | |
| 40Moderate | Sarepta Therapeutics, Inc. | Kathryn Jean Boor director | $94k 761 shares | -9% | |
| 50Moderate | Sarepta Therapeutics, Inc. | Hans Lennart Rudolf Wigzell director | $1.8M 15,000 shares | -40% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.